Dipeptidyl peptidase-IV inhibitors: Pharmacological profile and clinical use

Clinical Diabetes

Volumn 26, Issue 2, 2008, Pages 53-57

  White Jr , John R ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; GLUCAGON RELEASE; GLUCOSE HOMEOSTASIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RELEASE; INSULIN SYNTHESIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 42449084168     PISSN: 08918929     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaclin.26.2.53     Document Type: Review

References (35)

1. Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-IV inhibitors in type 2 diabetes. Lancet 368:1696-1705, 2006
2. Gonzalez C, Beruto V, Keller G, Santoro S, Di Girolamo G: Investigational treatments for type 2 diabetes mellitus: exenatide and liraglutide. Expert Opin Invest Drugs 15:887-895, 2006
3. Sudre B, Broqua P, White RB: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999001 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 51:1461-1469, 2002
4. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDH Zucker rat: a euglycemic- hyperinsulinemic clamp study. Diabetes 51:2677-2683, 2003
5. Januvia (sitagliptin) Tablets package insert. Whitehouse Station, N.J., Merck & Co., 2007
6. Aschner P, Kipnes M, Lunceford M, Sanchez M, Mickel C, Williams-Herman DE: Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 29:2632-2637, 2006
7. Aschner P, Kipnes M, Lunceford J, Sanchez M, Mickel C, Williams-Herman D: Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM) [Abstract]. Diabetes 55 (Suppl. 1):A462, 2006
8. Charbonnel B, Karasik A, Liu J, Wu M, Meininger G: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 29:2638-2643, 2006
9. Williams-Herman D, Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J: Initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin provides substantial glycemic improvements and HgbA1c goal attainment in patients with type 2 diabetes mellitus (T2DM) [Abstract]. Diabet Med 23 (Suppl. 4):319, 2006
10. Nauck M, Meininger G, Sheng D, Terranella L, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared to the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 9:194-205, 2007
11. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24 week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 28:1556-1568, 2006
12. Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P: Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Poster 556-P presented at the American Diabetes Association 66th Annual Meeting and Scientific Sessions in Washington D.C., June 2006
13. Karasik A, Charbonnel B, Liu J, Wu M, Meininger G: Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2diabetes. Poster 501-P presented at the American Diabetes Association 66th Annual Meeting and Scientific Sessions in Washington D.C., June 2006
14. Scott R, Wu M, Sanchez M, Stein P : Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 61:171-180, 2007
15. Deacon CF, Holst JJ: Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes. Int J Biochem Cell Biol 38:831-844, 2006
16. Kim D, Wang L, Beconi M, Eirman G, Fisher MH, Huaibing H, Hickey G, Kowalchick JE, Leiting B, Lyons K, Marsilio F, Mccann ME, Patel R, Petrov A, Scapin G, Patel S, Ranabir A, Singa R, Wu J, Wyvratt MJ, Zhang BB, Zhu L, Thornberry NA, Weber AE: (2R)4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4] triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Clin Endocrinol Metab 91:4612-4619, 2006
17. Lankas GR, Leiting B, Roy RS, Beconi M, Biftu E: Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 54:2988-2994, 2005
18. Vincent SH, Reed JR, Bergman AJ, Elmore CS, Zhu B, Xu S, Ebel D, Larson P, Zeng W, Chen L, Dilzer S, Lasseter K, Gottesdiener K, Wagner JA, Herman GA:. Metabolism and excretion of the DPP-4 inhibitor [14C] sitagliptin in humans. Drug Metab Dispos Electronically published 12 January 2007
19. Stevens C, Bergman AJ, Liu Q, Luo W, Wang AQ: Lack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV inhibitor [Abstract]. Clin Pharmacol Ther 79:P49, 2006
20. Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D: Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38:423-428, 2006
21. Ristic S, Byiers S, Foley J, Holmes D: Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 7:692-698, 2005
22. Mimori N, Terao S, Holmes D: Vildagliptin improves glucose control as evidenced by HbA1c after 12 weeks therapy in Japanese patients with type 2 diabetes [Abstract]. Diabetes 55 (Suppl. 1): Abstract 527-P, 2006
23. Nathwani A: The use of vildagliptin for treatment of patients with type 2 diabetes mellitus. Diabetes;55(Suppl. 1):Abstract 474-P, 2006
24. Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27:2874-2880, 2004
25. Baron MA, Rosenstock J, Bassiri B, Rochotte E, Cressien Y: Efficacy of vildagliptin combined with pioglitazone in patients with type 2 diabetes [Abstract]. Diabetologia 49 (Suppl. 1):A111, 2006
26. Fonseca V, DeJager S, Albrecht D, Shirt L, Schweizer A: Vildagliptin as add-on to insulin in patients with type 2 diabetes (T2DM) [Abstract]. Diabetes 55 (Suppl. 1):A111, 2006
27. Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab 7:423-428, 2005
28. Henness S, Keam SJ: Vildagliptin. Drugs 66:1989-2001, 2006
29. He YL, Sabo R, Balez S, Wang J, Campestrini A, Marion M, Ligueros-Saylan M: Absolute bioavailability of vildagliptin in healthy subjects. Clin Pharmacol Ther 79:38, 2006
30. He YL, Balch A, Campestrini J, Rivere G, Serra D, Prasad P, Ligueros-Saylan M: Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes. Clin Pharmacol Ther 77:56, 2005
31. Barilla D, He Y, Balez S, Bullock J, Ho Y, Gutierrez M, Ligueros-Saylan M: No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide [Abtsract]. Diabetes 53 (Suppl. 2):A470, 2004
32. Hughes TE, Mone MD, Russell ME, Weldon SC, Villhaur EB : NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-( S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry (Mosc) 38:11597-11603, 1999
33. He Y, Sabo R, Campestrini J, Wang Y, Ligueros-Saylan M, Lasseter K, Dilzer S, Howard D, Dole W: The influence of hepatic impairment on the pharmacokinetics of vildagliptin. Eur J Clin Pharmacol 63677-686, 2007
34. Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction. Diabetes 54 (Suppl. 1):528-529, 2005
35. He YL, Sabo R, Picard F, Wang Y, Campestini J, Herron J, Ligueros-Saylan M: Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ther 79:62, 2006